Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. Collaborate to Evaluate Stem Cell Culture Technologies Using Cellgorithm™ Platform
The collaboration will evaluate Ajinomoto Group’s stem cell culture products using Syntax Bio’s programmable stem cell differentiation platform to support improved regenerative medicine discovery, development, and manufacturing.
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture innovation and part of Ajinomoto Group, today announced a collaboration to evaluate Ajinomoto Group’s StemFit™ stem cell culture products using Syntax Bio’s proprietary Cellgorithm™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622105936/en/
Through the collaboration, AHN is providing Syntax Bio with StemFit™ stem cell culture media products to demonstrate Cellgorithm™ compatibility, performance and workflow optimization. Syntax Bio will evaluate StemFit™ and generate data to support their growing pipeline of cell therapy collaborations.
